Table 1.
RT n = 28, n (%) | CT and Immunotherapy n = 206, n (%) | TKI n = 42, n (%) | Total n = 276, n (%) | |
---|---|---|---|---|
Treatment on schedule | 0 | 14 (6.8) | 42 (100.0) | 56 (20.3) |
Switching from intravenous CT to an oral therapy | 0 | 23 (11.2) | 0 | 23 (8.3) |
Treatment interruption | 28 (100.0) | 169 (82.0) | 0 | 197 (71.4) |
Reports of suspicious symptoms associated with progression | 3/28 (10.7) | 44/169 (26.0) | NA | 50/197 (25.4) |
CT, chemotherapy; NA, not applicable; RT, radiotherapy; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TKI, tyrosine kinase inhibitor.